Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London : a retrospective cohort study
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance.
METHODS: Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed.
RESULTS: We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively.
CONCLUSIONS: Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
BMJ open respiratory research - 11(2024), 1 vom: 04. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Drysdale, Myriam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1MTK0BPN8V |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 11.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjresp-2023-002238 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37064753X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37064753X | ||
| 003 | DE-627 | ||
| 005 | 20240411232616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjresp-2023-002238 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM37064753X | ||
| 035 | |a (NLM)38575338 | ||
| 035 | |a (PII)e002238 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Drysdale, Myriam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London |b a retrospective cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance | ||
| 520 | |a METHODS: Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed | ||
| 520 | |a RESULTS: We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively | ||
| 520 | |a CONCLUSIONS: Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Respiratory Infection | |
| 650 | 4 | |a Viral infection | |
| 650 | 7 | |a sotrovimab |2 NLM | |
| 650 | 7 | |a 1MTK0BPN8V |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Galimov, Evgeniy R |e verfasserin |4 aut | |
| 700 | 1 | |a Yarwood, Marcus James |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Vishal |e verfasserin |4 aut | |
| 700 | 1 | |a Levick, Bethany |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbons, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Watkins, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Pierce, Benjamin F |e verfasserin |4 aut | |
| 700 | 1 | |a Lloyd, Emily J |e verfasserin |4 aut | |
| 700 | 1 | |a Kerr, William |e verfasserin |4 aut | |
| 700 | 1 | |a Birch, Helen J |e verfasserin |4 aut | |
| 700 | 1 | |a Kamalati, Tahereh |e verfasserin |4 aut | |
| 700 | 1 | |a Brett, Stephen J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open respiratory research |d 2013 |g 11(2024), 1 vom: 04. Apr. |w (DE-627)NLM244313849 |x 2052-4439 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:1 |g day:04 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjresp-2023-002238 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 1 |b 04 |c 04 | ||